戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 uiring surgical management similar to direct gastrointestinal infection.
2 l compound properties required to treat this gastrointestinal infection.
3 lays a key role in inflammatory diseases and gastrointestinal infection.
4 athogen, typically associated with foodborne gastrointestinal infection.
5 the detection of primary bacterial causes of gastrointestinal infection.
6 are important virulence factors required for gastrointestinal infection.
7 against EHEC O157:H7 using a murine model of gastrointestinal infection.
8 ible outcome in their patients with a recent gastrointestinal infection.
9 erance in a Caenorhabditis elegans model for gastrointestinal infection.
10 ll surface mucin, is an important barrier to gastrointestinal infection.
11 w role for T6SS as a key virulence factor in gastrointestinal infection.
12  and in vivo models to study B. pseudomallei gastrointestinal infection.
13 y response to limit invasive respiratory and gastrointestinal infection.
14  in addition to inlA appear to contribute to gastrointestinal infection.
15 rs (ABO, Lewis, and P) associated with other gastrointestinal infections.
16 le is a major cause of antibiotic-associated gastrointestinal infections.
17 e most common cause of antibiotic-associated gastrointestinal infections.
18 e (IBD) activity and can also be elevated in gastrointestinal infections.
19 d in the proportion of lower respiratory and gastrointestinal infections.
20 teria, opportunistic pathogens implicated in gastrointestinal infections.
21 italization for respiratory tract, skin, and gastrointestinal infections.
22 n therefore be effective in the treatment of gastrointestinal infections.
23 is a Gram-negative enteropathogen and causes gastrointestinal infections.
24 d as a preventative and treatment option for gastrointestinal infections.
25 ncluding bacteria that do not normally cause gastrointestinal infections.
26  prerequisite to protective immunity against gastrointestinal infections.
27 lmonella enterica serovar Typhimurium during gastrointestinal infections.
28 1917, a human probiotic strain used to treat gastrointestinal infections.
29 or their prophylactic or therapeutic role in gastrointestinal infections.
30 or the development of novel vaccines against gastrointestinal infections.
31 e to the development of new vaccines against gastrointestinal infections.
32  a nosocomial pathogen that can cause severe gastrointestinal infections.
33 otile bacterium, is a leading cause of human gastrointestinal infections.
34 eonates are considered highly susceptible to gastrointestinal infections.
35 l therapeutic strategies in the treatment of gastrointestinal infections.
36 s), enteritis necroticans, and non-foodborne gastrointestinal infections.
37 sures to new pathogenic organisms that cause gastrointestinal infections.
38  bowel diseases, food allergies and invasive gastrointestinal infections(1).
39 I) is a major cause of healthcare-associated gastrointestinal infections(1,2).
40 quently with azithromycin than with placebo: gastrointestinal infections (1647 vs. 1985 episodes; inc
41 1.8%), surgical-site infections (21.8%), and gastrointestinal infections (17.1%).
42 y infection (47.7%), malaria (29.7%), and/or gastrointestinal infection (19.7%).
43 er respiratory tract infections (171 [22%]), gastrointestinal infections (64 [8%]), eye, ear, nose, a
44    The most frequent serious infections were gastrointestinal infections (645 patients [38.9%]).
45 hat are associated with an increased risk of gastrointestinal infections across a population cohort o
46 effect of vitamin A supplementation on viral gastrointestinal infections among young children living
47     To investigate in a cohort with previous gastrointestinal infection and a control group the preva
48 n of inlA is important for cell invasion and gastrointestinal infection and suggest that sigmaB-regul
49 -3 (5-HT3) antagonists, and the treatment of gastrointestinal infections and chronic abdominal pain.
50 a for the treatment of patients with chronic gastrointestinal infections and inflammatory bowel disea
51                      The association between gastrointestinal infections and risk of MC was stronger
52 fficile is the most common hospital-acquired gastrointestinal infection, and nutrient acquisition is
53    All these patients are at similar risk of gastrointestinal infections, and the subsequent morbidit
54                                              Gastrointestinal infections are a frequent and important
55 asymptomatic viremia, respiratory tract, and gastrointestinal infections are the most common disease
56 is study, we report the human health risk of gastrointestinal infection associated with inhalation ex
57 ets may be beneficial in the defense against gastrointestinal infections, but their sustained activat
58 stressor exposure can have at the onset of a gastrointestinal infection by its ability to render a re
59 Ysa type III secretion (T3S) system enhances gastrointestinal infection by Yersinia enterocolitica bv
60                                 As for other gastrointestinal infections, C difficile disease is asso
61                             Shigellosis is a gastrointestinal infection caused by species of Shigella
62                                Children with gastrointestinal infections caused by Escherichia coli O
63                                              Gastrointestinal infection changes microbiome compositio
64                                 Treatment of gastrointestinal infections continues to be complicated
65                             The incidence of gastrointestinal infections continues to increase and in
66 ificantly increased rates of respiratory and gastrointestinal infection diagnoses (IR ratio, 2.64; 95
67                          We demonstrate that gastrointestinal infection does indeed occur in humans a
68 risk was higher among children who had had a gastrointestinal infection during the first year of life
69 o patient developed a clinically significant gastrointestinal infection during the study.
70                                     Repeated gastrointestinal infections during the first year of lif
71 produced in response to localized Salmonella gastrointestinal infection enable the pathogen to succes
72             Risk for IBD was not affected by gastrointestinal infections, gastrointestinal disease, o
73 both respiratory tract infections (RTIs) and gastrointestinal infections (GIIs).
74 e introduction of multiplex panels for human gastrointestinal infections has enhanced the identificat
75 es from children with severe respiratory and gastrointestinal infections has generated interest in un
76                                              Gastrointestinal infections have been linked to changes
77 d 2006-2007 regarding the development of any gastrointestinal infections, hospitalizations, and presc
78       It is preceded by upper respiratory or gastrointestinal infection in about two-thirds of cases
79 introduction of surveillance of outbreaks of gastrointestinal infection in England and Wales in 1992.
80 r respiratory tract infection in addition to gastrointestinal infection in gnotobiotic pigs, confirmi
81           Noroviruses are a leading cause of gastrointestinal infection in humans and mice.
82 ly manifests as a short-lived, self-limiting gastrointestinal infection in humans, however prolonged
83 SARS-CoV) which causes acute respiratory and gastrointestinal infection in humans.
84                                              Gastrointestinal infections in children are a major caus
85 plementation as a preventive measure against gastrointestinal infections in early childhood.
86 ost prevalent cause of antibiotic-associated gastrointestinal infections in health care facilities in
87 serovar Typhimurium (ST), a leading cause of gastrointestinal infections in humans, effects an overal
88 al presentation, diagnosis, and treatment of gastrointestinal infections in immunocompromised hosts i
89                                      Because gastrointestinal infections in immunocompromised persons
90 particularly during the past year, regarding gastrointestinal infections in immunocompromised persons
91 ess to treat antibiotic resistant topical or gastrointestinal infections in the age of antibiotic res
92 orted by the dose-response relationship) and gastrointestinal infections in the first year of life ma
93 al presentation, diagnosis, and treatment of gastrointestinal infections in the immunocompromised hos
94  article reviews what is new in the field of gastrointestinal infections in the immunocompromised hos
95 he pathogenesis, diagnosis, and treatment of gastrointestinal infections in the immunocompromised hos
96  diagnostic and therapeutic skills regarding gastrointestinal infections in the immunocompromised hos
97                                              Gastrointestinal infections in the immunocompromised hos
98 le is the leading cause of hospital-acquired gastrointestinal infections in the United States and one
99 piratory infections and HBoV2 to HBoV4 cause gastrointestinal infections in young children.
100 ses (HBoVs) may cause severe respiratory and gastrointestinal infections in young children.
101    This technology can also be used to study gastrointestinal infections, inflammatory bowel disease,
102 1.08), skin (IRR: 0.95; 95% CI: 0.76, 1.20), gastrointestinal infections (IRR: 1.03; 95% CI: 0.84, 1.
103      Their claimed benefit for counteracting gastrointestinal infection is linked predominantly to re
104 sible for causing bronchitis, pneumonia, and gastrointestinal infections, is highly resistant to UV d
105           These findings indicate that early gastrointestinal infections may be relevant for CD devel
106 vulnificus causes life-threatening wound and gastrointestinal infections, mediated primarily by the p
107                                   In a mouse gastrointestinal infection model, DeltasapA yielded sign
108 s in most hosts, then it is very likely that gastrointestinal infection occurs in humans as well.
109                                     Thus, if gastrointestinal infection occurs in most hosts, then it
110  show that following acute Toxoplasma gondii gastrointestinal infection of mice, control of commensal
111 ke infections, as some of the most important gastrointestinal infections of humankind.
112                                              Gastrointestinal infections often induce epithelial dama
113 n lansoprazole, all were free of significant gastrointestinal infections on long-term follow-up.
114 ism of Enterosgel action in the treatment of gastrointestinal infection or IBS is adsorption of targe
115         In a nationwide study, we found that gastrointestinal infection, particularly Clostridioides
116 , pulmonary, renal, endocrine and nutrition, gastrointestinal, infection, perioperative, and neurolog
117  levels of investment relative to burden for gastrointestinal infections ( pound254 million, 9.7%), s
118               Here we show that during acute gastrointestinal infection, priming of monocytes for reg
119 acteriophage formulation on the treatment of gastrointestinal infection, rats were infected with Salm
120 pment of vaccines against the most important gastrointestinal infections remains a high priority.
121 acid suppressing medications and the risk of gastrointestinal infections remains controversial.
122                                              Gastrointestinal infections represent a worldwide public
123 ed individuals, resulting in respiratory and gastrointestinal infections, respectively.
124                          In a mouse model of gastrointestinal infection, S. Typhimurium CadA activity
125 lial response, including host restriction of gastrointestinal infections such as HRV infection.
126 cin is far less effective against chlamydial gastrointestinal infection than against genital infectio
127 s, protozoans are more commonly the cause of gastrointestinal infections than are helminths.
128            Our results suggest that during a gastrointestinal infection, the immune response to comme
129  neuropathy often preceded by respiratory or gastrointestinal infections, though molecular testing of
130 is and treatment of pathologies ranging from gastrointestinal infections to diabetes.
131                  Here, we show that during a gastrointestinal infection, tolerance to commensals is l
132 itive bacillus, which is a frequent cause of gastrointestinal infections triggered by the depletion o
133 es isolated from patients with uncomplicated gastrointestinal infection using DNA microarray analysis
134         The prevalence of previous diagnosed gastrointestinal infection was 7.5% among patients with
135 genes with previously unproven phenotypes in gastrointestinal infection were tested in bovine ligated
136                                              Gastrointestinal infections were strongly associated wit
137 nterventions to improve gut health and treat gastrointestinal infections, which afflict millions glob
138                        It often occurs after gastrointestinal infection with E. coli O157:H7, which p
139                                        Acute gastrointestinal infection with intracellular pathogens
140                   The acute host response to gastrointestinal infection with invasive bacteria is cha
141 ical role for ILCs in the early responses to gastrointestinal infection with L. monocytogenes and ide
142 by acute renal failure, usually occurs after gastrointestinal infection with Shiga toxin 2 (Stx2)-pro
143         Typical HUS (ie, STEC-HUS) follows a gastrointestinal infection with STEC, whereas aHUS is as
144 although much less than that gained by prior gastrointestinal infection with the wild-type parent str
145 erosgel for bacterial toxins associated with gastrointestinal infection, with a lower than the compar
146   Campylobacter jejuni is a leading cause of gastrointestinal infections worldwide, due primarily to
147  chronic systemic inflammatory response to a gastrointestinal infection would similarly affect CNS pr

 
Page Top